Halfdan Sorbye

Summary

Affiliation: Haukeland University Hospital
Country: Norway

Publications

  1. doi request reprint Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients
    Halfdan Sorbye
    Department of Oncology, Haukeland University Hospital, Bergen, Norway
    Cancer 115:4679-87. 2009
  2. ncbi request reprint Age-dependent improvement in median and long-term survival in unselected population-based Nordic registries of patients with synchronous metastatic colorectal cancer
    H Sorbye
    Department of Oncology, Haukeland University Hospital, Bergen, Denmark
    Ann Oncol 24:2354-60. 2013
  3. pmc Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab
    Janne B Kjersem
    Department of Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
    BMC Cancer 12:534. 2012
  4. doi request reprint Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study
    H Sorbye
    Department of Oncology, Haukeland University Hospital, Bergen, Norway
    Ann Oncol 24:152-60. 2013
  5. doi request reprint Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983)
    Halfdan Sorbye
    Haukeland University Hospital, Bergen, Norway
    Ann Surg 255:534-9. 2012
  6. ncbi request reprint [Palliative chemotherapy and radiotherapy for metastatic colorectal cancer]
    Halfdan Sørbye
    Kreftavdelingen Haukeland Universitetssjukehus, 5021 Bergen
    Tidsskr Nor Laegeforen 128:194-7. 2008
  7. doi request reprint Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study
    Kjell Magne Tveit
    Department of Oncology, Oslo University Hospital, 0407 Oslo, Norway
    J Clin Oncol 30:1755-62. 2012
  8. doi request reprint Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study
    Line S Tarpgaard
    Department of Oncology, Odense University Hospital, Odense, Denmark and University of Southern Denmark, Odense, Denmark
    PLoS ONE 9:e87746. 2014
  9. doi request reprint Small cell lung cancer in a 14-year-old girl
    Håvard Trønnes
    Department of Pediatrics, Haukeland University Hospital, Bergen, Norway
    J Pediatr Hematol Oncol 34:e86-8. 2012

Collaborators

Detail Information

Publications9

  1. doi request reprint Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients
    Halfdan Sorbye
    Department of Oncology, Haukeland University Hospital, Bergen, Norway
    Cancer 115:4679-87. 2009
    ..Trial accrual patterns were examined to determine whether metastatic colorectal cancer (mCRC) patients enrolled in trials are representative of a general cancer population concerning patient characteristics and survival...
  2. ncbi request reprint Age-dependent improvement in median and long-term survival in unselected population-based Nordic registries of patients with synchronous metastatic colorectal cancer
    H Sorbye
    Department of Oncology, Haukeland University Hospital, Bergen, Denmark
    Ann Oncol 24:2354-60. 2013
    ..In metastatic colorectal cancer (mCRC) trials, median survival has increased from 6 months to above 20 months during the previous decades. Uncertainty exists in how this survival improvement has translated to the general mCRC population...
  3. pmc Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab
    Janne B Kjersem
    Department of Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
    BMC Cancer 12:534. 2012
    ....
  4. doi request reprint Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study
    H Sorbye
    Department of Oncology, Haukeland University Hospital, Bergen, Norway
    Ann Oncol 24:152-60. 2013
    ..As studies on gastrointestinal neuroendocrine carcinoma (WHO G3) (GI-NEC) are limited, we reviewed clinical data to identify predictive and prognostic markers for advanced GI-NEC patients...
  5. doi request reprint Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983)
    Halfdan Sorbye
    Haukeland University Hospital, Bergen, Norway
    Ann Surg 255:534-9. 2012
    ..We conducted an exploratory retrospective analysis to identify baseline factors possibly predictive for a benefit of perioperative FOLFOX on PFS...
  6. ncbi request reprint [Palliative chemotherapy and radiotherapy for metastatic colorectal cancer]
    Halfdan Sørbye
    Kreftavdelingen Haukeland Universitetssjukehus, 5021 Bergen
    Tidsskr Nor Laegeforen 128:194-7. 2008
    ..There are 3 450 new cases of colorectal cancer in Norway annually. In half of the patients, metastatic disease will evolve with time. Palliative chemo- or radiotherapy can prolong disease- and symptom control when cure is not feasible...
  7. doi request reprint Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study
    Kjell Magne Tveit
    Department of Oncology, Oslo University Hospital, 0407 Oslo, Norway
    J Clin Oncol 30:1755-62. 2012
    ..The influence of KRAS mutation status on treatment outcome was also investigated...
  8. doi request reprint Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study
    Line S Tarpgaard
    Department of Oncology, Odense University Hospital, Odense, Denmark and University of Southern Denmark, Odense, Denmark
    PLoS ONE 9:e87746. 2014
    ....
  9. doi request reprint Small cell lung cancer in a 14-year-old girl
    Håvard Trønnes
    Department of Pediatrics, Haukeland University Hospital, Bergen, Norway
    J Pediatr Hematol Oncol 34:e86-8. 2012
    ..The patient died of relapsing disease 21 months after initial diagnosis. Only 1 single case report on SCLC has been published earlier. Additional reports on pediatric SCLC are needed to evaluate appropriate treatment...